Ignite Creation Date:
2024-07-17 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06484816
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-26
Brief Title:
TGRX-1942 Chinese Phase I for Advanced Solid Tumor andor RelapsedRefractory Hematologic Malignancies
Sponsor:
Shenzhen TargetRx Inc
Organization:
Shenzhen TargetRx Inc
Study Overview
Official Title:
A Dose Escalation and Expansion Phase I Study Evaluating the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of TGRX-1942 in Patients With Advanced Solid Tumor andor RelapsedRefractory Hematologic Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase I study to evaluate the safety tolerability pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor andor relapsed or refractory hematological malignancies
Detailed Description:
This study is designed as a three-part study with dose escalation dose expansion and indication expansion phases Patients with advanced solid tumors will be initially enrolled to the study Other indications including solid tumors with specific gene mutations or other hematological malignancies with be considered for expansion phases with appropriate doses as evaluated at the end of dose escalation phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None